Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer

File Description SizeFormat 
Lung cancer review EJP Accepted version.pdfAccepted version496.08 kBAdobe PDFView/Open
Title: Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer
Authors: Haghgoo, SM
Allameh, A
Mortaz, E
Garssen, J
Folkerts, G
Barnes, PJ
Adcock, IM
Item Type: Journal Article
Abstract: Recent studies have been established high degree of genetic diversity in solid organ tumors among individuals and even between individual tumor cells. This intratumor and intertumor genetic diversity results in a heterogeneous tumor with unique characteristics which potentially allows effective drug therapy. The goal of pharmacogenomics is to elucidate the genetic network(s) that underlie drug efficacy and drug resistance. Advances in targeted and personalized therapy play an increasingly important role in many common cancers, notably lung cancer, due to the high incidence, prevalence, mortality and the greater tendency towards drug resistance seen in these patients. Non-small cell lung cancer (NSCLC) is characterized by mutations in the epidermal growth factor receptor (EGFR) and or downstream kinase pathways. This has led to the development of highly selective monoclonal antibodies and EGFR tyrosine kinase inhibitors (EGFR-TKIs) to prevent cancer initiation, proliferation, differentiation, angiogenesis, survival, and invasion. However, resistance to many of these new treatments is induced and further pharmacogenomic analysis has revealed mutations associated with increased or reduced drug efficacy. Combinations of kinase inhibitors or potentially the targeting of cancer stem cells may further increase the success of pharmacogenomics in treating patients with lung cancer.
Issue Date: 25-Feb-2015
Date of Acceptance: 17-Feb-2015
URI: http://hdl.handle.net/10044/1/51362
DOI: https://dx.doi.org/10.1016/j.ejphar.2015.02.029
ISSN: 0014-2999
Publisher: Elsevier
Start Page: 88
End Page: 97
Journal / Book Title: European Journal of Pharmacology
Volume: 754
Copyright Statement: Copyright © 2015 Elsevier B.V. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor/Funder: Medical Research Council (MRC)
Funder's Grant Number: G1001372
Keywords: Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Lung cancer
NSCLC
EGFR
K-Ras mutations
GROWTH-FACTOR RECEPTOR
ANAPLASTIC LYMPHOMA KINASE
ALDEHYDE DEHYDROGENASE 1
RET GENE FUSION
TYROSINE KINASE
STEM-CELLS
SIGNALING PATHWAY
KRAS MUTATIONS
EGFR MUTATIONS
PERSONALIZED MEDICINE
Angiogenesis Inhibitors
Animals
Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung
Humans
Lung Neoplasms
Models, Biological
Molecular Targeted Therapy
Mutation
Neoplastic Stem Cells
Protein Kinase Inhibitors
0801 Artificial Intelligence And Image Processing
1701 Psychology
1702 Cognitive Science
1115 Pharmacology And Pharmaceutical Sciences
Behavioral Science & Comparative Psychology
Publication Status: Published
Appears in Collections:National Heart and Lung Institute
Airway Disease
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons